Natural Killer Cells – Basic Biology to Clinical Translation
Presenting Sponsor Fate Therapeutics
February 15, 2019
7:00am-8:00am Light Breakfast and Networking
8:00am-10:00am Presentation with Q&A
10:00am-10:30am Break with Light Refreshments and Networking
11:00am-12:30pm Presentation with Q&A
La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037
No cost to attend. Carpooling is recommended. Limited Parking and Seating for this event.
Kindly register by February 9, 2019. Follow us on Twitter.
Hosts: Dan Kaufman, MD, PhD; Ezra Cohen, MD; Stephen Schoenberger, PhD
Speakers confirmed: Jack Bui, MD, PhD; Emily Mace, PhD; Karl-Johan Malmberg, PhD; Jeffrey Miller, MD; Silke Paust, PhD; Huang Zhu, PhD.
Jack Bui, MD
Recruitment of NK cells by Nrf2 and IL-17D, a paradigm for cancer inflammation?
Dr. Bui, MD, PhD, is a physician scientist who has expertise in the innate immune system and how it interacts with cancer cells. He directs a research laboratory focused on developing interventions that boost innate immune responses to cancer. Specific areas of expertise include IL-17 family cytokines, dendritic cells, natural killer cells, and macrophage polarization. His clinical niche encompasses immune monitoring, cellular therapy, and flow cytometry.
Emily Mace, PhD
Defining novel mechanistic requirements for human NK cell development
Emily Mace studies human natural killer cell development, particularly through the use of quantitative image analysis and cell biological approaches. This includes the use of highly spatially and temporally resolved and super-resolution microscopy to understand interactions between NK cell precursors and the microenvironment. She also identifies novel requirements for human NK cell development through the identification and study of rare patients with NK cell deficiencies. This has included the characterization of NK cell functional and cell biological phenotypes associated with GATA2, IRF8 and Coronin 1A deficiencies. She is an Assistant Professor of Pediatrics at Columbia University Irving Medical Center in New York, where she serves as the junior faculty representative to the American Association of Medical Colleges. She has published more than 60 papers and is an American Society for Hematology Scholar, as well as an Associate Member of the American Society for Cell Biology’s Women in Cell Biology Committee and a member of the Biophysical Society’s Committee for the Promotion of Women. Her work is funded by the National Institutes of Health-National Institute of Allergy and Infectious Diseases.
Karl-Johan Malmberg, PhD
How NK cells remember their education - Building functional potential through inhibition
Karl-Johan Malmberg is a Hematologist and Professor of Immunology at the University of Oslo, Norway and a Visiting Professor in Cell-Based Cancer Immunotherapy at the Karolinska Institute, Stockholm, Sweden. The Malmberg lab focuses on 1) basic questions concerning NK cell repertoire formation and regulation of effector cell function and 2) translational questions of how NK cells may be function-enabled for anti-cancer activity. The long-term goal of the laboratory is to advance our fundamental understanding of NK cell development and function, and use this progress to design new immunotherapeutic approaches and clinical trials for patients with cancer.
Jeffrey Miller, MD
Novel Strategies To Activate and Target NK Cells To Treat Cancer
Jeffrey S. Miller, MD, received a Bachelor of Science degree from Northwestern University in Evanston, Illinois and received his MD from Northwestern University School of Medicine. He completed an internship and residency in Internal Medicine at the University of Iowa in Iowa City. After completing a post-doctoral fellowship in Hematology, Oncology and Transplantation at the University of Minnesota, he joined the faculty in 1991. Dr. Miller is currently a Professor of Medicine at the University of Minnesota, Division of Hematology, Oncology and Transplantation. He has more than 20 years of experience studying the biology of NK cells and other immune effector cells and their use in clinical immunotherapy with over 170 peer-reviewed publications. He is a member of numerous societies such as the American Society of Hematology, the American Association of Immunologists, a member of the American Society of Clinical Investigation since 1999. He serves on the editorial board for Blood and is a reviewer for a number of journals and NIH grants. Dr. Miller was the recipient of the National Cancer Institute Outstanding Investigator Award for 2015.
Silke Paust, PhD
Both CTL and NK cells are required for successful immunotherapy to cure human solid tumor in a novel syngeneic patient derived xenograft model of lung cancer
Silke Paust is an Immunologist and Associate Professor in the Department of Immunology and Microbiology at The Scripps Research Institute in La Jolla, CA. Members of the Paust laboratory are interested in the development and testing of novel immunotherapies that elicit clinically relevant Natural Killer cell-mediated anti-viral and anti-tumor immunity. Our research program is centered on the discovery that subsets of NK cells are long-lived and capable of antigen-specific immunological memory to viruses and altered self, giving precedence to investigations that seek to exploit NK cell activity to prevent or cure disease. Using pre-clinical models and clinical samples, we are pursuing three specific goals: 1) Identification of the mechanisms by which subsets of murine and human NK cells mediate antigen-specific immunological memory responses. 2) Identification of NK cell-specific immune correlates of protection from viral infection or malignancy. 3) Development of effective, host-protective vaccine or therapeutic approaches that elicit potent NK cell-mediated recall responses in vivo. To enable our studies, we routinely utilize mouse models, xenograft models, and clinical samples for the immunological analyses of human innate and adaptive immune responses.
Huang Zhu, PhD
Dr. Zhu is postdoctoral researcher in Dr. Kaufman’s lab at department of medicine, UCSD. He focus on improving efficiency of producing natural killer cells from human ES cells and iPSCs suitable for new clinical applications to treat relapsed/refractory cancers. He is now aiming to engineer these NK cells with novel receptors such as CD16, chimeric antigen receptors (CAR) to improve anti-tumor activities. Dr. Zhu obtained his PhD in Molecular Biology at Shanghai Jiao Tong University, China. He then worked for a pharmaceutical company, Eli Lilly as research scientist for 4 plus years, focusing on pre-clinical drug discovery for diabetes, obesity and liver diseases.